Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors

作者：Yuejuan Cheng, Changting Meng, Hongyan Ying, Jian-Feng Zhou, Xiaoyan Yan, Xin Gao, Na Zhou, Chunmei Bai · 发表于：Medicine · 年份：2018 · DOI：10.1097/md.0000000000012750 · 被引用次数：12 · 研究领域：Neuroendocrine Tumor Research Advances、Lung Cancer Research Studies、Neuroblastoma Research and Treatments

The aim of the present study was to assess the effect of Endostar and temozolomide or dacarbazine plus 5-fluorouracil (5-FU) in patients with advanced pancreatic neuroendocrine tumors (pNETs).Phase II study of 14 patients with locally advanced or metastatic well-differentiated pNETs treated between April 2013 and September 2016. Patients received temozolomide or dacarbazine plus 5-FU, and Endostar. The primary outcome was the radiographic response rate.All 14 patients had nonfunctional pNETs. Six patients received temozolomide and 8 received dacarbazine + 5-FU, combined with Endostar. Thirteen patients were assessable for treatment response: 1(7%) with complete response, 5 (39%) with partial response, 5 (39%) with stable disease, and 2 (15%) with progression. The median progression-free survival was 12 months. The most common grade 1/2 toxicities were neutropenia (43%) and leucopenia (21%).Endostar combined with temozolomide or dacarbazine + 5-FU was effective in the treatment of advanced pNETs. The combinations were well tolerated.